The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1430341
Palinopsia associated to the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports
Provisionally accepted- Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
Cyclin inhibitors are recently incorporated drugs in the treatment of both metastatic and early-stage breast cancer. Following regulatory approval, their use has become commonplace in clinical practice. In recent months, uncommon toxicities related to the use of these drugs have been reported. To our knowledge, ocular toxicity associated with this treatment has not been reported. We report the clinical reports in two patients treated with Ribociclib and aromatase inhibitors, who experienced palinopsias as an early-onset ocular toxicity. This toxicity is not related to ophthalmological impairment and it decreases in intensity and frequency following dose adjustment. We believe that reporting uncommon toxicities can help professional care givers to recognized and to optimize the management of this drug.
Keywords: palinopsias, Ribociclib, breast cancer, adverse events, ophthalmologic toxicity
Received: 09 May 2024; Accepted: 31 Oct 2024.
Copyright: © 2024 MARTOS, Saint-Gerons Trecu, Mastfarré, Castro-Henriques, Martínez, Servitja and Albanell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
TAMARA MARTOS, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.